Literature DB >> 25151956

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.

S Z Usmani1, Q Zhang2, K Stratton3, P Qu3, S Yaccoby2, E Hansen3, D Steward2, S Panozzo2, N Petty2, A Hoering3, S Waheed2, F Van Rhee2, J Crowley3, B Barlogie2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25151956     DOI： 10.1038/leu.2014.248

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Pomalidomide.

Authors:  Martha Q Lacy; Arleigh R McCurdy
Journal:  Blood       Date:  2013-08-23       Impact factor: 22.113

2.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

Authors:  Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; Laura A Bruins; Jessica E Schmidt; Scott Van Wier; Xiu-Bao Chang; Chad C Bjorklund; Rafael Fonseca; P Leif Bergsagel; Robert Z Orlowski; A Keith Stewart
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

3.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Authors:  John D Shaughnessy; Pingping Qu; Saad Usmani; Christoph J Heuck; Qing Zhang; Yiming Zhou; Erming Tian; Ichiro Hanamura; Frits van Rhee; Elias Anaissie; Joshua Epstein; Bijay Nair; Owen Stephens; Ryan Williams; Sarah Waheed; Yazan Alsayed; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

4.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

5.  Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

Authors:  M Q Lacy; S R Hayman; M A Gertz; K D Short; A Dispenzieri; S Kumar; P R Greipp; J A Lust; S J Russell; D Dingli; S Zeldenrust; R Fonseca; P L Bergsagel; V Roy; J R Mikhael; A K Stewart; K Laumann; J B Allred; S J Mandrekar; S V Rajkumar; F Buadi
Journal:  Leukemia       Date:  2010-09-09       Impact factor: 11.528

6.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

7.  Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Authors:  Paul G Richardson; David Siegel; Rachid Baz; Susan L Kelley; Nikhil C Munshi; Jacob Laubach; Daniel Sullivan; Melissa Alsina; Robert Schlossman; Irene M Ghobrial; Deborah Doss; Nora Loughney; Laura McBride; Elizabeth Bilotti; Palka Anand; Lisa Nardelli; Sandra Wear; Gail Larkins; Min Chen; Mohamad H Zaki; Christian Jacques; Kenneth C Anderson
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

8.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

Authors:  S A Schey; P Fields; J B Bartlett; I A Clarke; G Ashan; R D Knight; M Streetly; A G Dalgleish
Journal:  J Clin Oncol       Date:  2004-07-12       Impact factor: 44.544

9.  Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

Authors:  Xavier Leleu; Michel Attal; Bertrand Arnulf; Philippe Moreau; Catherine Traulle; Gerald Marit; Claire Mathiot; Marie Odile Petillon; Margaret Macro; Murielle Roussel; Brigitte Pegourie; Brigitte Kolb; Anne Marie Stoppa; Bernadette Hennache; Sabine Bréchignac; Nathalie Meuleman; Beatrice Thielemans; Laurent Garderet; Bruno Royer; Cyrille Hulin; Lotfi Benboubker; Olivier Decaux; Martine Escoffre-Barbe; Mauricette Michallet; Denis Caillot; Jean Paul Fermand; Hervé Avet-Loiseau; Thierry Facon
Journal:  Blood       Date:  2013-01-14       Impact factor: 22.113

10.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Authors:  Paul G Richardson; David S Siegel; Ravi Vij; Craig C Hofmeister; Rachid Baz; Sundar Jagannath; Christine Chen; Sagar Lonial; Andrzej Jakubowiak; Nizar Bahlis; Kevin Song; Andrew Belch; Noopur Raje; Chaim Shustik; Suzanne Lentzsch; Martha Lacy; Joseph Mikhael; Jeffrey Matous; David Vesole; Min Chen; Mohamed H Zaki; Christian Jacques; Zhinuan Yu; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113
View more
  2 in total

Review 1.  Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review.

Authors:  Taiga Nishihori; Kenneth Shain
Journal:  Int J Genomics       Date:  2017-11-08       Impact factor: 2.326

2.  Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis.

Authors:  Runzhe Chen; Yujie Wang; Chengxin Luan; Chong Gao; Xiaoping Zhang; Baoan Chen
Journal:  J Cancer       Date:  2017-07-01       Impact factor: 4.207
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.